Berenberg Bank reaffirmed their buy rating on shares of Abcam (LON:ABC) in a report published on Monday, Digital Look reports. They currently have a GBX 1,330 ($17.38) price target on the stock.
Separately, Peel Hunt reiterated an add rating and issued a GBX 1,300 ($16.99) target price (down from GBX 1,430 ($18.69)) on shares of Abcam in a report on Monday.
LON ABC opened at GBX 1,146 ($14.97) on Monday. The company’s 50 day simple moving average is GBX 1,222.48 and its 200 day simple moving average is GBX 1,292.48. Abcam has a 12 month low of GBX 1,006 ($13.15) and a 12 month high of GBX 1,523 ($19.90). The company has a market capitalization of $2.38 billion and a P/E ratio of 41.08.
The firm also recently announced a dividend, which will be paid on Friday, November 29th. Investors of record on Thursday, November 7th will be issued a GBX 8.58 ($0.11) dividend. This is an increase from Abcam’s previous dividend of $3.55. This represents a dividend yield of 0.74%. The ex-dividend date is Thursday, November 7th. Abcam’s payout ratio is presently 0.43%.
In other Abcam news, insider Alan Thomas Hirzel bought 4,250 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were acquired at an average cost of GBX 1,139 ($14.88) per share, for a total transaction of £48,407.50 ($63,252.97).
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.
Featured Article: What are the benefits of a portfolio tracker?
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.